drugset
drugset / Trial / NCT03390062

A Study of Apatinib in Recurrent or Recurrent High-grade Glioma

NCT03390062 ↗

Phase 2 Unknown 30 enrolled West China Hospital Jiangsu HengRui Medicine Co., Ltd. · collab
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine the effectiveness and safety of Apatinib for patients with Recurrent or Recurrent High-grade Glioma.

Timeline

Start
2018-01-04
Primary completion
2019-12-20
Completion
2020-08-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Rivoceranib Small molecule 500 mg Oral

Indications

glioma